$GRTSQ
Gritstone bio, Inc. Stock $grtsq

$grtsq Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024025855 Filed on March 05, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.742M	$10.38M	$16.34M
YoY Change	-28.69%	143.62%	-18.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.502M	$7.916M	$28.78M
YoY Change	26.05%	17.08%	-0.65%
% of Gross Profit
Research & Development	$33.04M	$32.94M	$127.2M
YoY Change	8.28%	11.96%	14.16%
% of Gross Profit
Depreciation & Amortization	$1.742M	$1.921M	$7.591M
YoY Change	-3.17%	7.26%	15.72%
% of Gross Profit
Operating Expenses	$41.54M	$40.85M	$156.0M
YoY Change	11.5%	12.92%	11.11%
Operating Profit	-$39.80M		-$139.6M
YoY Change	14.32%		15.94%
Interest Expense	$1.296M	-$343.0K	$4.036M
YoY Change	53.55%	-154.53%	226.8%
% of Operating Profit
Other Income/Expense, Net		-$4.000K	-$32.00K
YoY Change
Pretax Income	-$40.39M	-$30.82M	-$138.5M
YoY Change	18.84%	-1.51%	15.71%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$40.39M	-$30.82M	-$138.5M
YoY Change	18.84%	-1.51%	15.71%
Net Earnings / Revenue	-2318.31%	-296.81%	-847.34%
Basic Earnings Per Share	-$0.34		-$1.20
Diluted Earnings Per Share	-$0.34	-$0.36	-$1.20
COMMON SHARES
Basic Shares Outstanding	98.07M	95.34M	115.5M
Diluted Shares Outstanding	118.4M		115.5M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.30M	$79.30M	$79.27M
YoY Change	-68.24%	-54.92%	-53.88%
Cash & Equivalents	$42.40M	$63.00M	$45.98M
Short-Term Investments	$3.908M	$16.30M	$16.29M
Other Short-Term Assets	$566.0K	$778.0K	$7.930M
YoY Change	-22.25%	37.21%	-23.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$51.85M	$87.44M	$87.44M
YoY Change	-66.5%	-52.19%	-52.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.09M	$17.28M	$84.12M
YoY Change	-30.82%	-19.0%	116.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$6.214M	$6.214M	$6.214M
YoY Change	-67.65%	-58.65%	-58.65%
Total Long-Term Assets	$85.36M	$90.33M	$90.33M
YoY Change	54.67%	56.08%	56.08%
TOTAL ASSETS
Total Short-Term Assets	$51.85M	$87.44M	$87.44M
Total Long-Term Assets	$85.36M	$90.33M	$90.33M
Total Assets	$137.2M	$177.8M	$177.8M
YoY Change	-34.65%	-26.16%	-26.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.248M	$3.819M	$3.819M
YoY Change	21.31%	-56.07%	-56.07%
Accrued Expenses	$2.141M	$1.213M	$21.17M
YoY Change	-31.44%	-70.59%	0.92%
Deferred Revenue	$1.285M	$2.350M
YoY Change	-54.12%	-54.2%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.87M	$27.34M	$27.34M
YoY Change	4.86%	-21.44%	-21.44%
LONG-TERM LIABILITIES
Long-Term Debt	$40.33M	$40.14M	$40.14M
YoY Change	36.36%	107.47%	107.47%
Other Long-Term Liabilities	$907.0K	$709.0K	$58.44M
YoY Change	261.35%	372.67%	269.31%
Total Long-Term Liabilities	$41.24M	$40.85M	$98.58M
YoY Change	38.25%	109.51%	180.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.87M	$27.34M	$27.34M
Total Long-Term Liabilities	$41.24M	$40.85M	$98.58M
Total Liabilities	$123.2M	$125.9M	$125.9M
YoY Change	78.43%	79.95%	79.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$699.9M	-$659.6M
YoY Change	26.09%	26.58%
Common Stock	$22.00K	$22.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.96M	$51.85M	$51.85M
YoY Change
Total Liabilities & Shareholders Equity	$137.2M	$177.8M	$177.8M
YoY Change	-34.65%	-26.16%	-26.16%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$40.39M	-$30.82M	-$138.5M
YoY Change	18.84%	-1.51%	15.71%
Depreciation, Depletion And Amortization	$1.742M	$1.921M	$7.591M
YoY Change	-3.17%	7.26%	15.72%
Cash From Operating Activities	-$33.60M	-$19.51M	-$121.6M
YoY Change	-16.21%	-35.77%	4.92%
INVESTING ACTIVITIES
Capital Expenditures	$143.0K	$191.0K	$4.572M
YoY Change	-90.87%	-87.12%	-22.14%
Acquisitions
YoY Change
Other Investing Activities	$12.45M	$38.49M	$106.9M
YoY Change	-45.27%	-186.16%	-1607.52%
Cash From Investing Activities	$12.30M	$38.29M	$102.3M
YoY Change	-41.89%	-182.98%	-889.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-379.0K	15.72M	25.12M
YoY Change	-104.38%	-75.58%	-69.77%
NET CHANGE
Cash From Operating Activities	-33.60M	-19.51M	-121.6M
Cash From Investing Activities	12.30M	38.29M	102.3M
Cash From Financing Activities	-379.0K	15.72M	25.12M
Net Change In Cash	-21.64M	34.50M	5.810M
YoY Change	110.74%	-383.73%	-112.68%
FREE CASH FLOW
Cash From Operating Activities	-$33.60M	-$19.51M	-$121.6M
Capital Expenditures	$143.0K	$191.0K	$4.572M
Free Cash Flow	-$33.74M	-$19.70M	-$126.2M
YoY Change	-19.02%	-38.16%	3.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001656634
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5959 Horton Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Emeryville
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94608
CY2023	dei	City Area Code CityAreaCode	510
CY2023	dei	Local Phone Number LocalPhoneNumber	871-6100
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	GRTS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	173700000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	98065594
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38663
CY2023	dei	Entity Registrant Name EntityRegistrantName	Gritstone bio, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4859534
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5959 Horton Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Emeryville
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94608
CY2023	dei	City Area Code CityAreaCode	510
CY2023	dei	Local Phone Number LocalPhoneNumber	871-6100
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	GRTS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	173700000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	98065594
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62986000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55498000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16288000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	116389000
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	14063000
CY2022	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	9131000
CY2021	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	8052000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1152000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-658000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3426000
CY2023	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	-4619000
CY2022	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	7387000
CY2021	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	614000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1968000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1879000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-419000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1142000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1290000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	593000
CY2023	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	-2362000
CY2022	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	3509000
CY2021	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	-859000
CY2023	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	353000
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62986000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55498000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16288000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16288000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	116389000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	116389000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2299000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2299000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	3977000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	3977000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5862000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5862000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7014000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7014000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	87435000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	87435000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	182878000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	182878000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17281000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17281000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21335000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21335000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	66839000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	66839000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17481000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17481000
CY2023Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	924000
CY2023Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	924000
CY2022Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	9739000
CY2022Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	9739000
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	4031000
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	4031000
CY2023Q4	us-gaap	Assets Assets	177769000
CY2023Q4	us-gaap	Assets Assets	177769000
CY2022Q4	us-gaap	Assets Assets	240754000
CY2022Q4	us-gaap	Assets Assets	240754000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3819000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3819000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8694000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2299000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	3977000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5862000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7014000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	87435000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	182878000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17281000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	66839000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17481000
CY2023Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	924000
CY2022Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	9739000
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	4031000
CY2023Q4	us-gaap	Assets Assets	177769000
CY2022Q4	us-gaap	Assets Assets	240754000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3819000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8694000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9357000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1213000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4124000
CY2023Q4	grts	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3696000
CY2022Q4	grts	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3343000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6904000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5294000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2350000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5131000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27339000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34801000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	709000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57727000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15673000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	40144000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19349000
CY2023Q4	us-gaap	Liabilities Liabilities	125919000
CY2022Q4	us-gaap	Liabilities Liabilities	69973000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8694000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9357000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8215000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1213000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4124000
CY2023Q4	grts	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3696000
CY2022Q4	grts	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3343000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6904000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5294000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2350000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5131000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27339000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34801000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	709000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57727000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15673000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	40144000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19349000
CY2023Q4	us-gaap	Liabilities Liabilities	125919000
CY2022Q4	us-gaap	Liabilities Liabilities	69973000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97585415
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97585415
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86894901
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86894901
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	22000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	711386000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	691910000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-80000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659561000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9357000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8215000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1213000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4124000
CY2023Q4	grts	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3696000
CY2022Q4	grts	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3343000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6904000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5294000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2350000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5131000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27339000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34801000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	709000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57727000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15673000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	40144000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19349000
CY2023Q4	us-gaap	Liabilities Liabilities	125919000
CY2022Q4	us-gaap	Liabilities Liabilities	69973000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97585415
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97585415
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86894901
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86894901
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	22000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	711386000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	691910000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-80000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659561000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521071000
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97585415
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97585415
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86894901
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86894901
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	22000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	711386000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	691910000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-80000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659561000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521071000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	51850000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	177769000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240754000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16344000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19945000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48214000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	127182000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97490000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28783000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28970000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25933000
CY2023	us-gaap	Operating Expenses OperatingExpenses	155965000
CY2022	us-gaap	Operating Expenses OperatingExpenses	140373000
CY2021	us-gaap	Operating Expenses OperatingExpenses	123423000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-139621000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-120428000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-75209000
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5199000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1976000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	164000
CY2023	us-gaap	Interest Expense InterestExpense	4036000
CY2022	us-gaap	Interest Expense InterestExpense	1235000
CY2021	us-gaap	Interest Expense InterestExpense	37000
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	32000
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138490000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521071000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	51850000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	170781000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	177769000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240754000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16344000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19945000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48214000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	127182000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	111403000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97490000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28783000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28970000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25933000
CY2023	us-gaap	Operating Expenses OperatingExpenses	155965000
CY2022	us-gaap	Operating Expenses OperatingExpenses	140373000
CY2021	us-gaap	Operating Expenses OperatingExpenses	123423000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-139621000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-120428000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-75209000
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5199000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1976000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	164000
CY2023	us-gaap	Interest Expense InterestExpense	4036000
CY2022	us-gaap	Interest Expense InterestExpense	1235000
CY2021	us-gaap	Interest Expense InterestExpense	37000
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	32000
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138490000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	83000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-7000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-73000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-138407000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119694000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75155000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.2
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.2
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115527546
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90918333
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	51850000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	170781000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	177769000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240754000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16344000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19945000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48214000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	127182000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	111403000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97490000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28783000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28970000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25933000
CY2023	us-gaap	Operating Expenses OperatingExpenses	155965000
CY2022	us-gaap	Operating Expenses OperatingExpenses	140373000
CY2021	us-gaap	Operating Expenses OperatingExpenses	123423000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-139621000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-75209000
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5199000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1976000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	164000
CY2023	us-gaap	Interest Expense InterestExpense	4036000
CY2022	us-gaap	Interest Expense InterestExpense	1235000
CY2021	us-gaap	Interest Expense InterestExpense	37000
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	32000
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	83000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-73000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-138407000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119694000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75155000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.2
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.2
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115527546
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90918333
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78885186
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	166739000
CY2021	grts	Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants	-451000
CY2021	grts	Stock Issued During Period Value Purchase Agreement StockIssuedDuringPeriodValuePurchaseAgreement	20830000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	914000
CY2021	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	49000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	83000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-7000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-73000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-138407000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119694000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75155000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.2
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.2
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115527546
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115527546
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90918333
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90918333
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78885186
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78885186
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	166739000
CY2021	grts	Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants	-451000
CY2021	grts	Stock Issued During Period Value Purchase Agreement StockIssuedDuringPeriodValuePurchaseAgreement	20830000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	914000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-73000
CY2021	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	49000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3360000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10552000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	216086000
CY2022	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	34000
CY2022	grts	Tax Payments Related To Shares Withheld For Vested Restricted Stock Units TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits	890000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	549000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12557000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	170781000
CY2023	grts	Tax Payments Related To Shares Withheld For Vested Restricted Stock Units TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits	946000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000
CY2023	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	34000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	801000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11618000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	83000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138490000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7591000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6560000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6347000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78885186
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78885186
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	166739000
CY2021	grts	Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants	-451000
CY2021	grts	Stock Issued During Period Value Purchase Agreement StockIssuedDuringPeriodValuePurchaseAgreement	20830000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	914000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-73000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3360000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10552000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	216086000
CY2022	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	34000
CY2022	grts	Tax Payments Related To Shares Withheld For Vested Restricted Stock Units TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits	890000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	549000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-7000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	186000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12557000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	170781000
CY2023	grts	Tax Payments Related To Shares Withheld For Vested Restricted Stock Units TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits	946000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000
CY2023	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	34000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	801000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11618000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	83000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138490000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	51850000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138490000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7591000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6560000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6347000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2698000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	372000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-817000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1412000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	392000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	11618000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	12557000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10552000
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1969000
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	14063000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3360000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	216086000
CY2022	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	34000
CY2022	grts	Tax Payments Related To Shares Withheld For Vested Restricted Stock Units TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits	890000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	549000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	186000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12557000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	170781000
CY2023	grts	Tax Payments Related To Shares Withheld For Vested Restricted Stock Units TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits	946000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000
CY2023	grts	Issuance Of Common Stock For Warrant Exercises Value IssuanceOfCommonStockForWarrantExercisesValue	34000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	801000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11618000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	83000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138490000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	51850000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138490000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7591000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6560000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6347000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2698000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	372000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-817000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1412000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	392000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1969000
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	14063000
CY2022	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	9131000
CY2021	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	8052000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1152000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-658000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3426000
CY2023	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	-4619000
CY2022	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	7387000
CY2021	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	614000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1968000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	372000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-817000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1412000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	392000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10552000
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1969000
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	14063000
CY2022	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	9131000
CY2021	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	8052000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1152000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-658000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3426000
CY2023	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	-4619000
CY2022	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	7387000
CY2021	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	614000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1968000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1879000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-419000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1142000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1290000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	593000
CY2023	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	-2362000
CY2022	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	3509000
CY2021	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	-859000
CY2023	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	353000
CY2022	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-363000
CY2021	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	2653000
CY2023	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-17290000
CY2022	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-8915000
CY2021	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-7925000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2781000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15198000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8633000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121648000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115946000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50678000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	26295000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	141908000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	199905000
CY2023	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	133208000
CY2022	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	9131000
CY2021	grts	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	8052000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1152000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-658000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3426000
CY2023	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	-4619000
CY2022	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	7387000
CY2021	grts	Increase Decrease In Deposit And Other Assets Noncurrent IncreaseDecreaseInDepositAndOtherAssetsNoncurrent	614000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1968000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1879000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-419000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1142000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	593000
CY2023	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	-2362000
CY2022	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	3509000
CY2021	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	-859000
CY2023	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	353000
CY2022	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-363000
CY2021	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	2653000
CY2023	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-17290000
CY2022	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-8915000
CY2021	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-7925000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2781000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15198000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8633000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121648000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115946000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50678000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	26295000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	141908000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	199905000
CY2023	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	133208000
CY2022	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	134816000
CY2021	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	87053000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4572000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5872000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5463000
CY2023	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2022	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2021	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	238000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	102341000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12964000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-118553000
CY2022	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	134816000
CY2021	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	87053000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4572000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5872000
CY2023	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2022	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	102341000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-419000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1142000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1290000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	593000
CY2023	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	-2362000
CY2022	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	3509000
CY2021	grts	Increase Decrease In Accrued And Other Liabilities Non Current IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent	-859000
CY2023	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	353000
CY2022	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-363000
CY2021	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	2653000
CY2023	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-17290000
CY2022	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-8915000
CY2021	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-7925000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2781000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15198000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8633000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121648000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115946000
CY2023	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	133208000
CY2022	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	134816000
CY2021	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	87053000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4572000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5872000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5463000
CY2023	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2022	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2021	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	238000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	102341000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12964000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-118553000
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19919000
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19130000
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2548000
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	420000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8394000
CY2023	grts	Payments Of Financing Lease PaymentsOfFinancingLease	240000
CY2022	grts	Payments Of Financing Lease PaymentsOfFinancingLease	228000
CY2021	grts	Payments Of Financing Lease PaymentsOfFinancingLease	56000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	946000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	890000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25117000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83098000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	108760000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5810000
CY2022	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-363000
CY2021	grts	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	2653000
CY2023	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-17290000
CY2022	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-8915000
CY2021	grts	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-7925000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2781000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15198000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8633000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121648000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115946000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50678000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	26295000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	141908000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	199905000
CY2023	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	133208000
CY2022	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	134816000
CY2021	grts	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	87053000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4572000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5872000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5463000
CY2023	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2022	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	0
CY2021	grts	Prepayments On Financing Lease PrepaymentsOnFinancingLease	238000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	102341000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12964000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-118553000
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19919000
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19130000
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2548000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8394000
CY2023	grts	Payments Of Financing Lease PaymentsOfFinancingLease	240000
CY2022	grts	Payments Of Financing Lease PaymentsOfFinancingLease	228000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	946000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	890000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25117000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83098000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	108760000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5810000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45812000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171048000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70575000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64765000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12964000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-118553000
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19919000
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19919000
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19130000
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19130000
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2548000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8394000
CY2023	grts	Payments Of Financing Lease PaymentsOfFinancingLease	240000
CY2022	grts	Payments Of Financing Lease PaymentsOfFinancingLease	228000
CY2021	grts	Payments Of Financing Lease PaymentsOfFinancingLease	56000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	946000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	890000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25117000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83098000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	108760000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45812000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-60471000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64765000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171048000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70575000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64765000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	133000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1146000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	738000
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	14000
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	2433000
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	69000
CY2023	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	706000
CY2022	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	1406000
CY2021	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	6452000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	553000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	109000
CY2023	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	59604000
CY2022	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	0
CY2021	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	0
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2415000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138500000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119700000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75100000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121600000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115900000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50700000
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2548000
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	420000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8394000
CY2023	grts	Payments Of Financing Lease PaymentsOfFinancingLease	240000
CY2022	grts	Payments Of Financing Lease PaymentsOfFinancingLease	228000
CY2021	grts	Payments Of Financing Lease PaymentsOfFinancingLease	56000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	946000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	890000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25117000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83098000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	108760000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5810000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45812000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-60471000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64765000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171048000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70575000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64765000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	133000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	738000
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	14000
CY2023	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	706000
CY2022	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	1406000
CY2021	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	6452000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	553000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	109000
CY2023	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	59604000
CY2022	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	0
CY2021	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	0
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138500000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119700000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75100000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121600000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115900000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659600000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521100000
CY2023Q4	grts	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	79300000
CY2023	grts	Period Not Covered By Companys Available Cash PeriodNotCoveredByCompanysAvailableCash	P12M
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45812000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64765000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171048000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70575000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64765000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110577000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	133000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1146000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	738000
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	14000
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	2433000
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	69000
CY2023	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	706000
CY2022	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	1406000
CY2021	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	6452000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	553000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	109000
CY2023	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	59604000
CY2022	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	0
CY2021	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	0
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2415000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	647000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138500000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119700000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75100000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121600000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115900000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50700000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659600000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521100000
CY2023Q4	grts	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	79300000
CY2023	grts	Period Not Covered By Companys Available Cash PeriodNotCoveredByCompanysAvailableCash	P12M
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55498000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	2299000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	133000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1146000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	738000
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	14000
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	2433000
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	69000
CY2023	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	706000
CY2022	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	1406000
CY2021	grts	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	6452000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	553000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	109000
CY2023	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	59604000
CY2022	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	0
CY2021	grts	Assets Acquired Under Leasing Obligations AssetsAcquiredUnderLeasingObligations	0
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138500000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119700000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75100000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121600000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115900000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50700000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659600000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521100000
CY2023Q4	grts	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	79300000
CY2023	grts	Period Not Covered By Companys Available Cash PeriodNotCoveredByCompanysAvailableCash	P12M
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3977000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	70575000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	70575000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	64765000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659600000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521100000
CY2023Q4	grts	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	79300000
CY2023	grts	Period Not Covered By Companys Available Cash PeriodNotCoveredByCompanysAvailableCash	P12M
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and including those related to revenue recognition, including but not limited to, transaction price and progress toward completion of performance obligation under the Company's contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62986000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and including those related to revenue recognition, including but not limited to, transaction price and progress toward completion of performance obligation under the Company's contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62986000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	2299000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3977000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and including those related to revenue recognition, including but not limited to, transaction price and progress toward completion of performance obligation under the Company's contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62986000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	2299000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3977000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	70575000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	64765000
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	62262000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, and including those related to revenue recognition, including but not limited to, transaction price and progress toward completion of performance obligation under the Company's contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62986000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55498000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	2299000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3977000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5290000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	70575000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	64765000
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	62262000
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2023, the Company has no off-balance sheet concentrations of credit risk.</span></p>
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2023, the Company has no off-balance sheet concentrations of credit risk.</span></p>
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2023, the Company has no off-balance sheet concentrations of credit risk.</span></p>
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2023, the Company has no off-balance sheet concentrations of credit risk.</span></p>
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	grts	Percentage Of Realization Of Tax Benefit Upon Ultimate Settlement PercentageOfRealizationOfTaxBenefitUponUltimateSettlement	0.50
CY2020Q2	grts	Use Of Net Operating Losses Suspension Period For Medium And Large Business UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness	P3Y
CY2020Q2	grts	Use Of Business Incentive Tax Credits Period Cap UseOfBusinessIncentiveTaxCreditsPeriodCap	P3Y
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	62262000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	62265000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	158691000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	55000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	135000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	158611000
CY2023Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	79300000
CY2022Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	175900000
CY2023	grts	Percentage Of Realization Of Tax Benefit Upon Ultimate Settlement PercentageOfRealizationOfTaxBenefitUponUltimateSettlement	0.50
CY2020Q2	grts	Use Of Net Operating Losses Suspension Period For Medium And Large Business UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness	P3Y
CY2020Q2	grts	Use Of Business Incentive Tax Credits Period Cap UseOfBusinessIncentiveTaxCreditsPeriodCap	P3Y
CY2023	grts	Percentage Of Realization Of Tax Benefit Upon Ultimate Settlement PercentageOfRealizationOfTaxBenefitUponUltimateSettlement	0.50
CY2020Q2	grts	Use Of Net Operating Losses Suspension Period For Medium And Large Business UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness	P3Y
CY2020Q2	grts	Use Of Business Incentive Tax Credits Period Cap UseOfBusinessIncentiveTaxCreditsPeriodCap	P3Y
CY2023	grts	Percentage Of Realization Of Tax Benefit Upon Ultimate Settlement PercentageOfRealizationOfTaxBenefitUponUltimateSettlement	0.50
CY2020Q2	grts	Use Of Net Operating Losses Suspension Period For Medium And Large Business UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness	P3Y
CY2020Q2	grts	Use Of Business Incentive Tax Credits Period Cap UseOfBusinessIncentiveTaxCreditsPeriodCap	P3Y
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	62262000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	62265000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	158691000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	55000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	135000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	158611000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	62265000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	158691000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	55000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	135000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	158611000
CY2023Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	79300000
CY2022Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	175900000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63000000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55500000
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	16300000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	120400000
CY2023	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2022	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2023	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2022	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48773000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	62265000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	158691000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	55000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	135000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	158611000
CY2023Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	79300000
CY2022Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	175900000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63000000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55500000
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	16300000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	120400000
CY2023	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2022	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2023	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2022	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	49681000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32415000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2023Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	79300000
CY2022Q4	grts	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	175900000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63000000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55500000
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	16300000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	120400000
CY2023	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2022	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2023	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2022	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	49681000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48773000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32415000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28782000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17281000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21335000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7600000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6600000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63000000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55500000
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	16300000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	120400000
CY2023	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2022	grts	Marketable Securities Realized Gain Loss Description MarketableSecuritiesRealizedGainLossDescription	no material realized gains or losses
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2023	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2022	grts	Fair Value Measurement Level1 To Level2 Transfers FairValueMeasurementLevel1ToLevel2Transfers	0
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	49681000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48773000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32415000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28782000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17281000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21335000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7600000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6600000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6300000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32415000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28782000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17281000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21335000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7600000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6600000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6300000
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	600000
CY2021Q1	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2021-04-01
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	13561000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7973000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	30000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021	us-gaap	Lease Cost LeaseCost	7973000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	17290000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	8915000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	7925000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	59604000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	553000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6562000
CY2023	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	706000
CY2022	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	1406000
CY2021	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	0
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28782000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17281000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21335000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7600000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6600000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6300000
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	600000
CY2021Q1	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2021-04-01
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	13561000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8797000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7973000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	30000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2023	us-gaap	Lease Cost LeaseCost	13591000
CY2022	us-gaap	Lease Cost LeaseCost	8797000
CY2021	us-gaap	Lease Cost LeaseCost	7973000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	17290000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	7925000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	59604000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	553000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6562000
CY2023	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	706000
CY2022	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	1406000
CY2021	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	0
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6300000
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	600000
CY2021Q1	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2021-04-01
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	13561000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8797000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7973000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	30000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021	us-gaap	Lease Cost LeaseCost	7973000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	17290000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	8915000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	7925000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	59604000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	553000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6562000
CY2023	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	706000
CY2022	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	1406000
CY2021	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	0
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.077
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.074
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	600000
CY2021Q1	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2021-04-01
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	13561000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8797000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7973000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	30000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2023	us-gaap	Lease Cost LeaseCost	13591000
CY2022	us-gaap	Lease Cost LeaseCost	8797000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	17290000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	8915000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	7925000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	59604000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	553000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6562000
CY2023	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	706000
CY2022	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	1406000
CY2021	grts	Increase In Right Of Use Assets From Lease Modifications IncreaseInRightOfUseAssetsFromLeaseModifications	0
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.077
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.074
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.077
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.074
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12834000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10749000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10376000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10466000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10732000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	41615000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	96772000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	32141000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6904000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57727000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40000000
CY2023Q4	grts	Final Fee FinalFee	2300000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-2156000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	40144000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	8457000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	18030000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	13513000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40000000
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.077
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.074
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12834000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10749000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10376000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10466000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10732000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	41615000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	96772000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	32141000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	64631000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6904000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57727000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40000000
CY2023Q4	grts	Final Fee FinalFee	2300000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-2156000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	40144000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	8457000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	18030000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	13513000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40000000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12834000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10749000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10376000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10466000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10732000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	41615000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	96772000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	32141000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	64631000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6904000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57727000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40000000
CY2023Q4	grts	Final Fee FinalFee	2300000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-2156000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	40144000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	8457000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	18030000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	13513000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40000000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12834000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10749000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10376000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10466000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10732000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	41615000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	96772000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	32141000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6904000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57727000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40000000
CY2023Q4	grts	Final Fee FinalFee	2300000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-2156000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	40144000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	8457000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	18030000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	13513000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40000000
CY2023Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	3904000
CY2022Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	4241000
CY2023Q4	grts	Collaboration Receivable CollaborationReceivable	14000
CY2022Q4	grts	Collaboration Receivable CollaborationReceivable	135000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	940000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1158000
CY2022Q4	grts	Interest And Other Receivables Current InterestAndOtherReceivablesCurrent	529000
CY2023Q4	grts	Facilities Related Deposits FacilitiesRelatedDeposits	9000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	778000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	567000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5862000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7014000
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	924000
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	934000
CY2023Q4	grts	Prepaid Expense For Research And Development Non Current PrepaidExpenseForResearchAndDevelopmentNonCurrent	0
CY2022Q4	grts	Prepaid Expense For Research And Development Non Current PrepaidExpenseForResearchAndDevelopmentNonCurrent	643000
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	0
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	8162000
CY2023Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	924000
CY2022Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	9739000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97585415
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97585415
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86894901
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86894901
CY2023Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	3904000
CY2022Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	4241000
CY2023Q4	grts	Collaboration Receivable CollaborationReceivable	14000
CY2022Q4	grts	Collaboration Receivable CollaborationReceivable	135000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	940000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1158000
CY2023Q4	grts	Interest And Other Receivables Current InterestAndOtherReceivablesCurrent	217000
CY2022Q4	grts	Interest And Other Receivables Current InterestAndOtherReceivablesCurrent	529000
CY2023Q4	grts	Facilities Related Deposits FacilitiesRelatedDeposits	9000
CY2022Q4	grts	Facilities Related Deposits FacilitiesRelatedDeposits	384000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	778000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	567000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5862000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7014000
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	924000
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	934000
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	0
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	8162000
CY2023Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	924000
CY2022Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	9739000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97585415
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86894901
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86894901
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the Company’s common stock are entitled to one vote per share.
CY2023Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	3904000
CY2022Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	4241000
CY2023Q4	grts	Collaboration Receivable CollaborationReceivable	14000
CY2022Q4	grts	Collaboration Receivable CollaborationReceivable	135000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	940000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1158000
CY2022Q4	grts	Interest And Other Receivables Current InterestAndOtherReceivablesCurrent	529000
CY2023Q4	grts	Facilities Related Deposits FacilitiesRelatedDeposits	9000
CY2022Q4	grts	Facilities Related Deposits FacilitiesRelatedDeposits	384000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	778000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	567000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5862000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7014000
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	924000
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	934000
CY2023Q4	grts	Prepaid Expense For Research And Development Non Current PrepaidExpenseForResearchAndDevelopmentNonCurrent	0
CY2022Q4	grts	Prepaid Expense For Research And Development Non Current PrepaidExpenseForResearchAndDevelopmentNonCurrent	643000
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	0
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	8162000
CY2023Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	924000
CY2022Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	9739000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97585415
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97585415
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86894901
CY2023Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	3904000
CY2022Q4	grts	Prepaid Expense For Research And Development PrepaidExpenseForResearchAndDevelopment	4241000
CY2023Q4	grts	Collaboration Receivable CollaborationReceivable	14000
CY2022Q4	grts	Collaboration Receivable CollaborationReceivable	135000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	940000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1158000
CY2022Q4	grts	Interest And Other Receivables Current InterestAndOtherReceivablesCurrent	529000
CY2023Q4	grts	Facilities Related Deposits FacilitiesRelatedDeposits	9000
CY2022Q4	grts	Facilities Related Deposits FacilitiesRelatedDeposits	384000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	778000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	567000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5862000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7014000
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	924000
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	934000
CY2023Q4	grts	Prepaid Expense For Research And Development Non Current PrepaidExpenseForResearchAndDevelopmentNonCurrent	0
CY2022Q4	grts	Prepaid Expense For Research And Development Non Current PrepaidExpenseForResearchAndDevelopmentNonCurrent	643000
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	0
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	8162000
CY2023Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	924000
CY2022Q4	grts	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	9739000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97585415
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97585415
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86894901
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86894901
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the Company’s common stock are entitled to one vote per share.
CY2022Q1	grts	Maximum Securities Covered Under Registration Agreement MaximumSecuritiesCoveredUnderRegistrationAgreement	250000000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20489256
CY2022	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	3442567
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.73
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.2
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.03
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4814394
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6951620
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.92
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y29D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1089000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	4775796
CY2023	grts	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted	4227353
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	712566
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.2
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.76
CY2023	grts	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled	824088
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86894901
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the Company’s common stock are entitled to one vote per share.
CY2022Q1	grts	Maximum Securities Covered Under Registration Agreement MaximumSecuritiesCoveredUnderRegistrationAgreement	250000000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20489256
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.03
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4814394
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6951620
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.92
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y29D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1089000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	4775796
CY2023	grts	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted	4227353
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	712566
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.2
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.76
CY2023	grts	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled	824088
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	200000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6997158
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.6
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y2M19D
CY2022	grts	Share Based Compensation Arrangement By Sharebased Payment Award Options Exercised Cash Received ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedCashReceived	200000
CY2021	grts	Share Based Compensation Arrangement By Sharebased Payment Award Options Exercised Cash Received ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedCashReceived	3400000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8500000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M1D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7800000
CY2023	grts	Stock Based Compensation Expense And Awards Granted To Non Employees StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees	800000
CY2022	grts	Stock Based Compensation Expense And Awards Granted To Non Employees StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees	600000
CY2021	grts	Stock Based Compensation Expense And Awards Granted To Non Employees StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees	700000
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the Company’s common stock are entitled to one vote per share.
CY2022Q1	grts	Maximum Securities Covered Under Registration Agreement MaximumSecuritiesCoveredUnderRegistrationAgreement	250000000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20489256
CY2022	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	3442567
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.73
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.2
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.03
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4814394
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6951620
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.92
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y29D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1089000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	4775796
CY2023	grts	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted	4227353
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	712566
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.2
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.76
CY2023	grts	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled	824088
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	384725
CY2022Q1	grts	Maximum Securities Covered Under Registration Agreement MaximumSecuritiesCoveredUnderRegistrationAgreement	250000000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20489256
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.73
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.2
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.03
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4814394
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6951620
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.92
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y29D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1089000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	4775796
CY2023	grts	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted	4227353
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	712566
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.2
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.76
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	200000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6997158
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.6
CY2022	grts	Share Based Compensation Arrangement By Sharebased Payment Award Options Exercised Cash Received ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedCashReceived	200000
CY2021	grts	Share Based Compensation Arrangement By Sharebased Payment Award Options Exercised Cash Received ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedCashReceived	3400000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	561526
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3514787
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	871385
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.64
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	115958
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	3.29
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3088970
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	384725
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.35
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	200000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	254000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000
CY2022	grts	Share Based Compensation Arrangement By Sharebased Payment Award Options Exercised Cash Received ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedCashReceived	200000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	561526
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.38
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3514787
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	871385
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.64
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	115958
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	3.29
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3088970
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.29
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11618000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12557000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10552000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	27700000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	33900000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	112904000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	112904000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	109191000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.35
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	6186925
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7273461
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	264000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4647325
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.53
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y8M1D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	200000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6997158
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.6
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y2M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	254000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5800000
CY2022	grts	Share Based Compensation Arrangement By Sharebased Payment Award Options Exercised Cash Received ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedCashReceived	200000
CY2021	grts	Share Based Compensation Arrangement By Sharebased Payment Award Options Exercised Cash Received ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedCashReceived	3400000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8500000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M1D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7800000
CY2022	grts	Stock Based Compensation Expense And Awards Granted To Non Employees StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees	600000
CY2021	grts	Stock Based Compensation Expense And Awards Granted To Non Employees StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees	700000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	561526
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.38
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3514787
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	871385
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.64
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	115958
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	3.29
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3088970
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.29
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	27700000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	33900000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	112904000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	109191000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	561526
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.38
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3514787
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.29
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12557000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10552000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.076
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.102
CY2023	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.007
CY2022	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.004
CY2021	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.019
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.029
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.018
CY2023	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2022	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2021	grts	Non Taxable Stock Premium NonTaxableStockPremium	0.025
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.20
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.283
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	27700000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	33900000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11618000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12557000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10552000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.076
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.102
CY2023	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.007
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.019
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.029
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.018
CY2023	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2022	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2021	grts	Non Taxable Stock Premium NonTaxableStockPremium	0.025
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.20
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.337
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11618000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12557000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10552000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.102
CY2023	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.007
CY2022	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.004
CY2021	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.019
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.029
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.018
CY2023	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2022	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2021	grts	Non Taxable Stock Premium NonTaxableStockPremium	0.025
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.20
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.283
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.337
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.076
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.102
CY2023	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.007
CY2022	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.004
CY2021	grts	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential	-0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.019
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.029
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.018
CY2023	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2022	grts	Non Taxable Stock Premium NonTaxableStockPremium	0
CY2021	grts	Non Taxable Stock Premium NonTaxableStockPremium	0.025
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.20
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.283
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.337
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	27700000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	33900000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	112904000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	109191000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	18038000
CY2022Q4	grts	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6031000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4685000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	109191000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	18038000
CY2022Q4	grts	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6031000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4685000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3786000
CY2023Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	9344000
CY2022Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	9437000
CY2023Q4	grts	Deferred Tax Assets Other Depreciation DeferredTaxAssetsOtherDepreciation	593000
CY2022Q4	grts	Deferred Tax Assets Other Depreciation DeferredTaxAssetsOtherDepreciation	449000
CY2023Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	41571000
CY2022Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	21434000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160877000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q1	grts	Increased In Deferred Tax Assets Capitalized Expense IncreasedInDeferredTaxAssetsCapitalizedExpense	20100000
CY2023	grts	Ownership Interest Change Over Period OwnershipInterestChangeOverPeriod	P3Y
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6715000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5481000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4025000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	77000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8213000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1234000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1456000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14851000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6715000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5481000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	18038000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	14877000
CY2023Q4	grts	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	18506000
CY2022Q4	grts	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6031000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4685000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3786000
CY2023Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	9344000
CY2022Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	9437000
CY2023Q4	grts	Deferred Tax Assets Other Depreciation DeferredTaxAssetsOtherDepreciation	593000
CY2022Q4	grts	Deferred Tax Assets Other Depreciation DeferredTaxAssetsOtherDepreciation	449000
CY2023Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	41571000
CY2022Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	21434000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	205641000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	165905000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	188663000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160877000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	16978000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5028000
CY2023Q4	grts	Deferred Tax Liabilities Other Depreciation DeferredTaxLiabilitiesOtherDepreciation	0
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q1	grts	Increased In Deferred Tax Assets Capitalized Expense IncreasedInDeferredTaxAssetsCapitalizedExpense	20100000
CY2023	grts	Ownership Interest Change Over Period OwnershipInterestChangeOverPeriod	P3Y
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6715000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5481000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4025000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	77000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8213000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1234000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	18038000
CY2022Q4	grts	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6031000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4685000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3786000
CY2023Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	9344000
CY2022Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	9437000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0
CY2022Q4	grts	Deferred Tax Assets Other Depreciation DeferredTaxAssetsOtherDepreciation	449000
CY2023Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	41571000
CY2022Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	21434000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	205641000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	165905000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	188663000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160877000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	16978000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5028000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q1	grts	Increased In Deferred Tax Assets Capitalized Expense IncreasedInDeferredTaxAssetsCapitalizedExpense	20100000
CY2023	grts	Ownership Interest Change Over Period OwnershipInterestChangeOverPeriod	P3Y
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6715000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5481000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4025000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	77000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8213000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1234000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1456000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14851000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3786000
CY2023Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	9344000
CY2022Q4	grts	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	9437000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	700000
CY2023Q4	grts	Deferred Tax Assets Other Depreciation DeferredTaxAssetsOtherDepreciation	593000
CY2022Q4	grts	Deferred Tax Assets Other Depreciation DeferredTaxAssetsOtherDepreciation	449000
CY2023Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	41571000
CY2022Q4	grts	Deferred Tax Assets Capitalized Expense DeferredTaxAssetsCapitalizedExpense	21434000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	205641000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	165905000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	188663000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160877000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	16978000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5028000
CY2023Q4	grts	Deferred Tax Liabilities Other Depreciation DeferredTaxLiabilitiesOtherDepreciation	0
CY2022Q4	grts	Deferred Tax Liabilities Other Depreciation DeferredTaxLiabilitiesOtherDepreciation	0
CY2023Q4	grts	Deferred Tax Liabilities Operating Lease Right Of Uset Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets	16978000
CY2022Q4	grts	Deferred Tax Liabilities Operating Lease Right Of Uset Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets	5028000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q1	grts	Increased In Deferred Tax Assets Capitalized Expense IncreasedInDeferredTaxAssetsCapitalizedExpense	20100000
CY2023	grts	Ownership Interest Change Over Period OwnershipInterestChangeOverPeriod	P3Y
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6715000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5481000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4025000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	77000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8213000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1234000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1456000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14851000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6715000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115527546
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115527546
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90918333
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78885186
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.2
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2022	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	3442567
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10623005
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7707343
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5879131
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1300000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1456000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14851000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5481000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115527546
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115527546
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90918333
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90918333
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78885186
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.2
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2022	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	3442567
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10623005
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7707343
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5879131
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6715000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5481000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138490000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115527546
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115527546
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90918333
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78885186
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.2
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2023	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	6359371
CY2022	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	3442567
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10623005
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7707343
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5879131
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1300000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-138490000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119687000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-75082000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115527546
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115527546
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90918333
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90918333
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78885186
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78885186
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.2
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.2
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2023	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	6359371
CY2022	grts	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	3442567
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10623005
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7707343
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5879131
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1300000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1300000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000950170-24-025855-index-headers.html	Edgar Link	pending
0000950170-24-025855-index.html	Edgar Link	pending
0000950170-24-025855.txt	Edgar Link	pending
0000950170-24-025855-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
grts-20231231.htm	Edgar Link	pending
grts-20231231.xsd	Edgar Link	pending
grts-ex10_10.htm	Edgar Link	pending
grts-ex10_27.htm	Edgar Link	pending
grts-ex10_30.htm	Edgar Link	pending
grts-ex23_1.htm	Edgar Link	pending
grts-ex31_1.htm	Edgar Link	pending
grts-ex31_2.htm	Edgar Link	pending
grts-ex32.htm	Edgar Link	pending
grts-ex97_1.htm	Edgar Link	pending
img98007937_0.jpg	Edgar Link	pending
img98007937_1.jpg	Edgar Link	pending
img98007937_2.jpg	Edgar Link	pending
img98007937_3.jpg	Edgar Link	pending
img98007937_4.jpg	Edgar Link	pending
img98007937_5.jpg	Edgar Link	pending
img98007937_6.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
0000950170-24-025855-index-headers.html	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
0000950170-24-025855-index.html	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
0000950170-24-025855.txt	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
0000950170-24-025855-xbrl.zip	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R50.htm	Edgar Link	pending
grts-20231231.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
grts-20231231.xsd	Edgar Link	pending
R52.htm	Edgar Link	pending
grts-ex10_10.htm	Edgar Link	pending
grts-ex10_27.htm	Edgar Link	pending
grts-ex10_30.htm	Edgar Link	pending
grts-ex23_1.htm	Edgar Link	pending
grts-ex31_1.htm	Edgar Link	pending
grts-ex31_2.htm	Edgar Link	pending
grts-ex32.htm	Edgar Link	pending
grts-ex97_1.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
img98007937_0.jpg	Edgar Link	pending
img98007937_1.jpg	Edgar Link	pending
img98007937_2.jpg	Edgar Link	pending
R54.htm	Edgar Link	pending
img98007937_3.jpg	Edgar Link	pending
R55.htm	Edgar Link	pending
img98007937_4.jpg	Edgar Link	pending
R56.htm	Edgar Link	pending
img98007937_5.jpg	Edgar Link	pending
R57.htm	Edgar Link	pending
img98007937_6.jpg	Edgar Link	pending
R58.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R59.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
grts-20231231_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
grts-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GRTSQ
Gritstone bio, Inc. Stock $grtsq

2024 Q1 Form 10-K Financial Statement

#000095017024025855 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRTSQ Gritstone bio, Inc. Stock $grtsq

2024 Q1 Form 10-K Financial Statement

#000095017024025855 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRTSQ
Gritstone bio, Inc. Stock $grtsq